NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Key Terms

regulatory t-cell medical

Regulatory T cell (often called a Treg) is a type of white blood cell that acts like a brake or thermostat for the immune system, calming or shutting down immune reactions to prevent damage to healthy tissue. For investors, Tregs matter because drugs or therapies that boost, block, or reprogram these cells can treat a range of conditions—autoimmune disease, transplant rejection, and cancer—so changes in Treg science can drive new drug pipelines and market opportunities.

treg medical

Treg, short for regulatory T cell, is a type of immune cell that acts like a brake on the immune system, calming or suppressing immune responses to prevent excessive inflammation or attack on the body's own tissues. For investors, therapies that boost or block Tregs can change the commercial outlook for drugs treating autoimmune diseases, organ transplant rejection or cancer, because shifting this balance can determine a treatment’s effectiveness and safety.

phagocytes medical

Phagocytes are a type of white blood cell that find, engulf and remove harmful microbes, dead cells and debris from the body—think of them as the immune system’s garbage collectors and first responders. For investors, their activity is central to how many drugs, vaccines and diagnostics work or are tested, and changes in phagocyte behavior can be a key safety signal, efficacy marker or therapeutic target.

immunometabolic medical

Immunometabolic describes the interaction between the immune system and the body's metabolism — how immune cells use and change energy and nutrients, and how metabolic states influence immune behavior. For investors, therapies or diagnostics that target immunometabolic pathways can open new treatment approaches for cancers, autoimmune and metabolic diseases, much like tuning both a thermostat and a fuel supply to make a system run healthier and more efficiently.

autoimmune medical

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

neurodegenerative medical

Neurodegenerative describes diseases where nerve cells in the brain or spinal cord progressively lose function and die, causing worsening movement, memory or other mental abilities over time. For investors this matters because such conditions create large, long-term needs for therapies and caregiving; developing treatments often requires lengthy, expensive research and regulatory testing but can lead to substantial, sustained market opportunities if a therapy proves effective — like fixing the wiring in a whole neighborhood rather than a single house.

apoptotic medical

Apoptotic describes cells undergoing apoptosis, a programmed, orderly process in which a cell essentially dismantles and disposes of itself—like a worn appliance being safely decommissioned to avoid causing damage. For investors, labeling a drug or biomarker as apoptotic signals a specific mechanism of action that can mean effective removal of diseased cells (important for cancer treatments) or possible harm to healthy tissue, affecting trial outcomes, regulatory review and commercial prospects.

nasdaq financial

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models

Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood

Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis and psoriasis, providing a compelling and unparalleled pipeline in-a-drug potential

BLACKSBURG, Va.--(BUSINESS WIRE)-- NImmune Biopharma (“NImmune”), a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company, will present first-ever preclinical and translational data demonstrating the therapeutic potential of LANCL2-targeting immunometabolic therapeutics for the treatment of psoriasis at IMMUNOLOGY2026, the Annual Meeting of the American Association of Immunologists (AAI), taking place April 15–19, 2026. The abstract, “Pharmacological activation of LANCL2 is a novel immunometabolic mechanism for the treatment of psoriasis,” will be presented among other peer‑reviewed scientific abstracts highlighting emerging research and therapeutic innovations in immunology.

The results highlight the potential of a LANCL2 immunometabolic platform, with oral NIM-1324 and topical omilancor demonstrating robust efficacy in multiple preclinical models of psoriasis by engaging downstream immune and metabolic pathways. LANCL2 therapeutics reprogram immune cell metabolism to enhance regulatory T‑cell (Treg)–mediated anti‑inflammatory functions, reduce pro‑inflammatory mediators, and increase apoptotic cell clearance and metabolism by phagocytes. Together, the findings support the potential of the LANCL2 pathway to deliver therapeutic benefit in a wide range of human diseases.

Oral NIM‑1324 is a de-risked next‑generation, once‑daily, small‑molecule LANCL2 therapeutic designed for systemic exposure. Novel data demonstrate that NIM-1324 significantly ameliorates disease severity and inflammation in multiple preclinical models of psoriasis. Importantly, pharmacological activation of LANCL2 reduced the production of pro‑inflammatory mediators in human blood cells derived from patients with psoriasis, providing translational evidence that the observed preclinical effects may extend to human disease biology.

Now operating as a new, wholly-dedicated clinical program and business venture founded by Dr. Josep Bassaganya-Riera, NIM-1324 is a Phase 2-ready therapeutic for the treatment of ulcerative colitis, Crohn’s disease, lupus, rheumatoid arthritis and psoriasis with several follow-on indications for other inflammatory, autoimmune and neurodegenerative diseases—including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease—also advancing at pace.

“Psoriasis is a chronic inflammatory disease with a substantial impact on quality of life, and there remains an unmet clinical need for safer, more effective long-term treatment options,” said Dr. Bassaganya‑Riera, Executive Chairman, President and CEO of NImmune Biopharma. “What is particularly compelling about these findings is the consistency of benefit we continue to observe across a wide range of inflammatory, autoimmune and neurodegenerative diseases when the LANCL2 pathway is pharmacologically activated. By selectively enhancing immunoregulatory pathways rather than broadly suppressing the immune system, and uniquely reprogramming metabolism to maximize anti-inflammatory actions, LANCL2 therapeutics offer the potential for durable efficacy with an improved safety and tolerability profile.”

These results reflect more than two decades of sustained scientific collaboration and platform development led by Dr. Bassaganya‑Riera and colleagues. Through a unique collaborative scientific innovation ecosystem consisting of NImmune, BioTherapeutics, the NIMML Institute, and Dr. Bassaganya-Riera’s latest clinical program for the development of NIM-1324, transdisciplinary teams are identifying novel immunoregulatory mechanisms of action and accelerating the development of first-in-class and best-in-class therapeutics from discovery through clinical testing. This unique ecosystem that rapidly translates data into actionable R&D strategy has previously demonstrated significant clinical and commercial success having enabled the foundation of Landos Biopharma in 2017, a company that Dr. Bassaganya-Riera built from the ground up, took public (NASDAQ: LABP) in 2021 and was acquired by AbbVie, Inc. (NYSE: ABBV) in May 2024.

“This unique R&D ecosystem has yielded an expandable therapeutic pipeline of immunoregulatory drug candidates grounded in transformative scientific discoveries at the intersection of immunology and metabolism,” added Dr. Bassaganya‑Riera. “We are now seeing consistent signals of therapeutic efficacy across inflammatory bowel disease, lupus, rheumatoid arthritis, psoriasis, asthma, multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. These novel findings further support the science, clinical validation and commercial potential of LANCL2 activation, the pipeline-in-a-drug promise of NIM-1324 and the strength of a seasoned, transdisciplinary drug development team behind this innovative platform.”

About NImmune Biopharma

NImmune is a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that leverages a proprietary A.I. platform to rapidly and capital efficiently develop novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases. Underpinned by the TITAN-X computational platform that utilizes advanced A.I., advanced computational modeling, and bioinformatics and biomedical research capabilities to pioneer innovation in the development and commercialization of novel best-in-class I&I therapies, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates to New Drug Application (NDA) filing and commercialization. Additional information: www.NIMMUNEBIO.COM.

About NIMML

The NIMML Institute is a 501 (c) (3) non-profit foundation dedicated to combining advanced computational modeling using A.I. with translational research and clinical testing to accelerate development of the next wave of precision medicines for inflammatory and autoimmune diseases. The NIMML Institute applies its TITAN-X advanced A.I.-powered platform to large-scale transdisciplinary projects aimed at solving important public health problems through precision medicine. The Institute is headquartered in Blacksburg, VA. For more information, please visit www.NIMML.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260324351143/en/

Media Contact

Alex Jeffrey / Jonathan Warren

Gasthalter & Co.

nimmune@gasthalter.com

212‑257‑4170

Source: NImmune Biopharma